Mastering Acute Respiratory Failure and NIV Guidelines for SCE

Introduction

Acute respiratory failure is one of the highest-yield topics in the Specialty Certificate Examination (SCE) for Acute Internal Medicine. It appears repeatedly across multiple question formats—often disguised within complex clinical vignettes that test not just your knowledge of guidelines, but your ability to apply them under pressure. Whether it's a COPD patient with a rising CO₂, a patient with cardiogenic pulmonary oedema, or an immunocompromised patient with pneumonia, the principles of non-invasive ventilation (NIV) are essential knowledge.

This guide distils the key guidelines, evidence, and clinical pearls you need to confidently tackle acute respiratory failure questions in your SCE.

Classification of Acute Respiratory Failure

Understanding the distinction between Type 1 and Type 2 respiratory failure is fundamental—SCE questions often begin with an arterial blood gas (ABG) that you must interpret correctly before selecting management.

Type 1 Respiratory Failure

• Definition: Hypoxaemia (PaO₂ < 8 kPa) with normal or low PaCO₂

• Common causes: Pneumonia, pulmonary embolism, ARDS, pulmonary oedema, asthma

• Key principle: Oxygenation failure—V/Q mismatch or shunt

Type 2 Respiratory Failure

• Definition: Hypoxaemia (PaO₂ < 8 kPa) with hypercapnia (PaCO₂ > 6 kPa)

• Common causes: COPD exacerbation, neuromuscular weakness, obesity hypoventilation syndrome, drug overdose

• Key principle: Ventilatory failure—alveolar hypoventilation

SCE Tip: Always check the ABG carefully. A "normal" PaO₂ in a patient on high-flow oxygen may still represent significant hypoxaemia. Calculate the A-a gradient if needed.

Emergency Oxygen Therapy: The Foundation

Before discussing NIV, you must master the BTS emergency oxygen guidelines (2017 update), as SCE questions frequently test oxygen prescribing.

Key Principles:

Critical SCE Points:

• Oxygen is a drug—prescribe it with a target range

• Use controlled oxygen for COPD patients (28% Venturi mask)

• Do not withhold oxygen from breathless COPD patients who are not hypercapnic—target 88–92% and check ABG

• If pH < 7.35 with PaCO₂ > 6 kPa despite optimal medical therapy → consider NIV

Non-Invasive Ventilation (NIV): BTS Guidelines

The British Thoracic Society (BTS) published comprehensive NIV guidelines (2008, updated 2017) that form the backbone of SCE questions on this topic. Let's break down the essential components.

When to Use CPAP vs BiPAP

This is perhaps the most commonly tested distinction:

BiPAP Settings for COPD Exacerbation

The BTS recommends a standardised approach to initiating BiPAP in COPD:

1. Initial settings: IPAP 10–15 cmH₂O, EPAP 4–5 cmH₂O

2. Titrate up: Increase IPAP by 2–5 cmH₂O increments every 10 minutes

3. Target: IPAP 15–20 cmH₂O (or higher if tolerated)

4. Oxygen: Add supplemental oxygen to maintain SpO₂ 88–92%

5. Monitor: ABG at 1 hour, then 1–2 hourly

SCE Exam Trap: Do not increase EPAP to improve oxygenation in COPD—this increases the work of breathing. Increase IPAP to improve ventilation and reduce CO₂. Add oxygen to the circuit to improve SpO₂.

Indications for NIV in COPD (BTS Criteria)

If pH < 7.25: Consider intensive care involvement early—NIV may fail, and invasive ventilation may be needed.

Cardiogenic Pulmonary Oedema and CPAP

The 3CPO trial (2009) is a landmark study frequently referenced in SCE questions:

3CPO Trial Key Findings:

• Design: Multicentre RCT comparing standard oxygen, CPAP, and BiPAP in acute cardiogenic pulmonary oedema

• Population: 1,069 patients

• Primary outcome: 7-day mortality

• Results: No significant difference in 7-day mortality between groups

• Secondary outcomes: CPAP and BiPAP reduced the need for intubation compared to standard oxygen

• Conclusion: NIV does not reduce mortality but improves symptoms and reduces need for invasive ventilation

SCE Clinical Application:

• CPAP is first-line NIV mode for cardiogenic pulmonary oedema

• BiPAP is not routinely recommended (may worsen outcomes in some studies, though 3CPO showed no difference)

• Start at 5–7.5 cmH₂O and titrate to clinical response

• Treat the underlying cause simultaneously (diuretics, vasodilators)

• NIV is a bridge to definitive treatment, not a substitute

NIV in Pneumonia: A Nuanced Approach

Pneumonia management with NIV is more complex and frequently tested:

Community-Acquired Pneumonia (CAP):

• NIV may be considered in selected patients with Type 1 respiratory failure

• Less evidence than for COPD or pulmonary oedema

• Higher failure rate (40–50%)

• Use as a trial—if no improvement in 1–2 hours, escalate

Immunocompromised Patients:

• Early NIV is recommended for respiratory failure in immunocompromised patients

• Evidence shows improved survival compared to invasive ventilation

• This is a high-yield SCE point—immunocompromised patients with pneumonia should receive early NIV rather than waiting for deterioration

CURB-65 and NIV Decision-Making:

SCE Pearl: When a question describes an immunocompromised patient (e.g., post-chemotherapy, post-transplant) with pneumonia and respiratory failure, the answer often involves early NIV rather than invasive ventilation.

Contraindications to NIV

SCE questions frequently test knowledge of when NIV is not appropriate. Memorise these:

Absolute Contraindications:

• Cardiac or respiratory arrest

• Inability to protect airway (reduced GCS)

• Facial deformity/trauma/burns preventing mask fit

• Recent upper GI surgery (risk of gastric insufflation)

• Copious respiratory secretions (risk of aspiration)

• Agitated/uncooperative patient (relative—may resolve with explanation)

Relative Contraindications:

• Haemodynamic instability (SBP < 90 mmHg)

• Severe arrhythmias

• Confusion (may improve with NIV if due to hypercapnia)

• Pneumothorax (drain before NIV if possible)

• Bowel obstruction

SCE Trap: Confusion due to hypercapnia is not an absolute contraindication to NIV—it may actually improve with treatment. However, if the patient is unable to cooperate or protect their airway, invasive ventilation is required.

Monitoring During NIV

The SCE may ask about monitoring requirements during NIV:

Essential Monitoring:

1. Continuous: SpO₂, ECG, clinical observation

2. Hourly (initial): Respiratory rate, heart rate, blood pressure, conscious level, mask comfort, synchrony

3. ABG: At 1 hour after initiation, then 1–4 hourly depending on response

4. Settings review: Check IPAP, EPAP, FiO₂, leak, trigger sensitivity

Signs of NIV Failure:

• Persisting acidosis (pH < 7.25 after 1–2 hours)

• Worsening PaCO₂

• Increasing respiratory distress

• Falling GCS

• Haemodynamic deterioration

• Patient intolerance despite optimisation

Action point: If NIV is failing, do not simply increase settings indefinitely. Escalate to invasive mechanical ventilation if the patient is a suitable candidate. Consider the ceiling of care if NIV has been set as the ceiling.

Ceiling of Care and NIV

This is a critical ethical and clinical area tested in SCE questions:

Key Principles:

• NIV may be used as a ceiling of treatment in patients who are not candidates for invasive ventilation

• This decision should be made early and documented clearly

• Involve the patient (if possible), family, and MDT

• NIV as a ceiling is appropriate in: advanced COPD, end-stage respiratory disease, Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) decisions

• NIV as a ceiling is not appropriate if the reversible cause has a high probability of resolution with invasive ventilation

SCE Scenario Example:

A 78-year-old with severe COPD (FEV₁ 30% predicted), on long-term oxygen, presents with exacerbation. pH 7.28, PaCO₂ 9.2 kPa. CURB-65 = 0. What is the most appropriate management?

Answer: Initiate BiPAP with controlled oxygen (target SpO₂ 88–92%), treat the exacerbation (nebulised salbutamol/ipratropium, IV hydrocortisone, antibiotics if bacterial infection suspected), and assess response. If the patient deteriorates despite optimised NIV, review the ceiling of care—in this case, NIV may be an appropriate ceiling given the advanced COPD.

Key Evidence for SCE

Familiarising yourself with landmark trials will help you answer evidence-based questions:

SCE Question Patterns and How to Approach Them

Pattern 1: ABG Interpretation + Management

Format: Patient presents with breathlessness → ABG given → choose next management step

Strategy:

1. Identify Type 1 vs Type 2 failure

2. Check pH—if < 7.35, this is acute-on-chronic or acute respiratory acidosis

3. Apply BTS criteria for NIV

4. Choose the correct mode (CPAP for Type 1, BiPAP for Type 2)

Pattern 2: NIV Failure Scenario

Format: Patient on NIV → ABG shows worsening → what next?

Strategy:

1. Check settings—are they optimised? (IPAP 15–20, correct oxygen)

2. Check for complications (pneumothorax, aspiration, mask leak)

3. If settings optimised and patient deteriorating → escalate to ICU

4. Consider ceiling of care if patient not for invasive ventilation

Pattern 3: Mode Selection

Format: Clinical scenario → choose CPAP vs BiPAP vs invasive ventilation

Strategy:

• Cardiogenic pulmonary oedema → CPAP

• COPD with hypercapnia → BiPAP

• Immunocompromised + pneumonia → early NIV (BiPAP or CPAP depending on ABG)

• GCS < 8 → invasive ventilation

• Facial trauma → invasive ventilation

Clinical Scenario for Practice

A 68-year-old man with known COPD (FEV₁ 35% predicted, on salmeterol/fluticasone and tiotropium, ex-smoker) presents to the Acute Medicine Unit with 3 days of worsening breathlessness, productive cough with purulent sputum, and reduced exercise tolerance. On arrival: RR 28, SpO₂ 84% on air, HR 110, BP 135/85, temp 37.8°C, GCS 15.

Initial management: Controlled oxygen (28% Venturi mask, target SpO₂ 88–92%), nebulised salbutamol 5 mg + ipratropium 500 mcg, IV hydrocortisone 100 mg, oral amoxicillin 500 mg (CURB-65 = 1).

ABG after 1 hour (on 28% oxygen): pH 7.29, PaCO₂ 8.5 kPa, PaO₂ 7.8 kPa, HCO₃⁻ 32 mmol/L, BE +6.

Questions to consider:

1. What type of respiratory failure? → Type 2 (hypoxia + hypercapnia)

2. What is the acid-base status? → Acute-on-chronic respiratory acidosis (pH low, HCO₃⁻ elevated suggesting chronic CO₂ retention)

3. What is the next step? → Initiate BiPAP (meets BTS criteria: pH 7.25–7.35, PaCO₂ > 6 kPa)

4. What initial settings? → IPAP 10–15, EPAP 4–5, FiO₂ to maintain SpO₂ 88–92%

5. When to reassess? → ABG at 1 hour

Expected improvement: pH should improve to > 7.35 and PaCO₂ should fall within 1–2 hours if NIV is effective.

Common Pitfalls in SCE

1. Choosing CPAP for COPD — COPD with hypercapnia requires BiPAP, not CPAP

2. Withholding oxygen in COPD — Give controlled oxygen (target 88–92%), don't leave patient hypoxic

3. Forgetting to treat the underlying cause — NIV is supportive; antibiotics, diuretics, bronchodilators must be given simultaneously

4. Missing immunocompromised patients — These patients benefit from early NIV; don't wait for deterioration

5. Not recognising NIV failure — If pH doesn't improve after 1–2 hours, escalate; don't keep increasing IPAP indefinitely

6. Confusing ceiling of care with treatment failure — NIV as a ceiling is a planned decision, not a fallback when invasive ventilation fails

7. Ignoring patient comfort — NIV success depends on patient tolerance; choose the right interface and explain the treatment

Summary Checklist for SCE

Conclusion

Acute respiratory failure and NIV represent a core competency in Acute Internal Medicine that the SCE examines from multiple angles—from ABG interpretation to mode selection, from evidence-based practice to ethical decisions about ceiling of care. By mastering the BTS guidelines, understanding the key trials, and practising clinical scenarios, you'll be well-equipped to approach these questions with confidence.

Remember: in the SCE, the correct answer often lies not in the most aggressive intervention, but in the most appropriate one—guided by guidelines, evidence, and the individual patient's clinical context.